Background: Gemcitabine and docetaxel chemotherapy protocols have proven efficacy in the treatment of metastatic soft tissue sarcomas. Doxorubicin is also a commonly used treatment both as a single agent and as a part of combination therapies. This phase 2 study was designed to assess the efficacy and safety of a combination regimen of gemcitabine, docetaxel , and doxorubicin. Methods: This is a single institution study of advanced sarcoma pateints who were refractory to 1^st line chemotherapy. Adequate performance status, organ function, and measurable disease (RECIST v1.1) were required. Patients received Gemcitabine (400 mg/m2), Doxorubicin (20 mg/m2) and Docetaxel (20 mg/m2) on days 1 and 8 of a 21 day cycle, and must have completed 2 cycles in order to be evaluable. Disease assessment was completed using the RECIST 1.1 criteria and toxicity was evaluated using the NCI CTCAE version 4.2. Results: A total of 32 patients were enrolled from 08/2011 - 08/2014 and 31 patients received at least 2 cycles of therapy. Pts with leiomyosarcoma (n = 7) liposarcoma (7) synovial sarcoma (2), chondrosarcoma (2), bone tumors (6), and others (8). The majority of patients (n = 21, 66%) previously received doxorubicin and many (n = 8, 25%) had previously received gemcitabine and docetaxel in combination. The average number of previous regimens was 3 previous chemotherapies (range, 1 to 7). The median age was 49 (range, 21 – 69). A median of 5 cycles of gemcitabine, docetaxel and doxorubicin were given (range, 1-12). A partial response was seen in 16 % of patients (5/31), and stable disease > 3 months in 39% (12/31). Clinical benefit (CR+PR+SD > 3months) was 17/31 55% (95% CI .36 -0.7) Grade 3 and 4 hematologic toxicities were observed in 14 patients (thrombocytopenia 12 pts, and neutropenia 2 pts) however, no patients were discontinued for toxicity. Conclusions: The combination of gemcitabine, doxorubicin, and docetaxel is an active regimen with a manageable toxicity profile in patients with advanced and pre-treated soft tissue and bone sarcomas.